MichaelJohnMauroMD
Hematology • New York, NYLeader, Myeloproliferative Disorders Program; Professor, Member and Attending Physician, Memorial Sloan Kettering Cancer Center
Dr. Mauro is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1275 York Avenue
Box 489
New York, NY 10065Phone+1 212-639-3107Fax+1 212-772-8550- Is this information wrong?
Summary
- Dr. Michael Mauro is a hematologist in New York, NY and is affiliated with Memorial Sloan-Kettering Cancer Center. He received his medical degree from Geisel School of Medicine at Dartmouth and has been in practice 23 years. He is experienced in healthcare outcomes research, bcr-abl positive chronic myelogenous leukemia, antineoplastic agents, bcr-abl fusion proteins, and chromosome aberrations.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 1997 - 2000- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1994 - 1997
Geisel School of Medicine at DartmouthClass of 1994
Certifications & Licensure
FL State Medical License 2021 - Present
OR State Medical License 2000 - Present
NJ State Medical License 2018 - 2025
NY State Medical License 1996 - 2024
NC State Medical License 2020 - 2022
ME State Medical License 2020 - 2021
OK State Medical License 2020 - 2021
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia Start of enrollment: 2008 May 01
- Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML Start of enrollment: 2008 Aug 14
- A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL Start of enrollment: 2014 Apr 24
Publications & Presentations
PubMed
- CML and the WHO: Why?Ellin Berman, Neil P Shah, Michael Deninger, Jessica K Altman, Maria Amaya, Kebede Begna, Ravi Bhatia, Onyee Chan, Robert Collins, Peter Curtin, Daniel J DeAngelo, Mic...> ;Journal of Clinical Oncology. 2024 Mar 20
- Project Confirm: Accelerated Drug Approvals for CML-Response.Norsworthy, K. J., Norsworthy, K. J., Norsworthy, K. J., Kendra L Sweet, Jorge E Cortes, Jane F Apperley, Mel Mann, Michael J Mauro, Vivian G Oehler, Cristina Ruiz, Ch...> ;Clinical Cancer Research. 2024 Jan 5
- 1 citationsEstimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia.Winn, A., Deininger, M., Moore, J., Shah, N., Flynn, K., Atallah, E., Cortes, J., Kota, V., Larson, R., Mauro, M., Oehler, V., Pinilla-Ibarz, J., Radich, J., Thompson, J.> ;JAMA Network Open. 2023 Dec 1
- Join now to see all
Abstracts/Posters
- Cytogenetic and Molecular Response with First- and Second-Generation Tyrosine Kinase Inhibitor (TKI) Therapy in Simplicity: An Observational Study of Patients with Chr...Michael J. Mauro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Phase 1 Trial of K0706, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): In Patients with Chronic Myelogenous Leukemia (CML) and Phildelphia Positive Acute Lymph...Michael J. Mauro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II StudyMichael J. Mauro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- A multicenter, randomized phase III study of asciminib (ABL001) versus bosutinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously t...2019 ASCO Annual Meeting - 6/1/2019
- Cardiovascular Mortality Among CML Patients in the Pre-TKI and TKI Eras: A SEER Analysis 1992-20042018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Dosing Patterns of Dasatinib Use in Simplicity, an Observational Study in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients (pts) in Routine Clinical Practice2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Authored Content
- Efficacy and Safety Outcomes by Baseline Comorbidity and Age in Patients Newly Diagnosed with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Treated with Dasatinib or Imatinib in DASISIONOctober 2017
Press Mentions
Molecular Monitoring Deficient in Older Adults with CMLMay 2nd, 2023- Comparing Asciminib with Bosutinib in Patients with Chronic-Phase Chronic Myeloid LeukemiaDecember 17th, 2021
Do Additional Chromosomal Abnormalities Noted at CML Diagnosis Affect Response and Survival?November 16th, 2017- Join now to see all
Hospital Affiliations
Memorial Sloan Kettering Cancer CenterNew York, New York- Memorial Hospital for Cancer and allied DiseasesBasking Ridge, New Jersey
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
